MiR-654-5p attenuates breast cancer progression by targeting EPSTI1.

Tan, Yu-Yan; Xu, Xiao-Yun; Wang, Jin-Feng; Zhang, Cheng-Wu; Zhang, Sheng-Chu

Tan, Yu-Yan; Xu, Xiao-Yun; Wang, Jin-Feng; Zhang, Cheng-Wu; Zhang, Sheng-Chu.

Afiliação

Tan YY; Department of General Surgery, The First College of Clinical Medical Science, China Three Gorges UniversityYichang 443003, Hubei, China; Department of General Surgery, Zhongda Hospital, School of Medicine, Southeast UniversityNanjing 210009, Jiangsu, China.
Xu XY; Department of Intensive Care Unit, The First College of Clinical Medical Science, China Three Gorges University Yichang 443003, Hubei, China.
Wang JF; Department of General Surgery, The First College of Clinical Medical Science, China Three Gorges University Yichang 443003, Hubei, China.
Zhang CW; Department of General Surgery, The First College of Clinical Medical Science, China Three Gorges University Yichang 443003, Hubei, China.
Zhang SC; Department of General Surgery, The First College of Clinical Medical Science, China Three Gorges University Yichang 443003, Hubei, China.

Am J Cancer Res ; 6(2): 522-32, 2016.

Article em En | MEDLINE | ID: mdl-27186421

Palavras-chave

EPSTI1; breast cancer; miR-654-5p; miRNA; survival

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Cancer Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google